Phase I, Open-Label Study With Dendritic Cell therapy (MesoPher) In Combination With Extended- Pleurectomy/Decortication After Chemotherapy in Subjects With Resectable Mesothelioma.

Studiedetails

Type carcinoma: Mesothelioom
Stadium: I - IIIA
Mutatie: n/a
Lijn: 1ste
Site: Erasmus MC
Contactgegevens:

long.oncologie@erasmusmc.nl

Website: https://-/

 Inclusiecriteria

  • Patients with a histologically confirmed diagnosis of epithelioid MPM who are eligible
    for 2 to 4 cycles of platinum-based chemotherapy. Patients who progressed after chemotherapy
    will not be discontinued from the trial if they are still eligible for eP/D and none
    of the exclusion criteria is present (e.g. local progression with only focal chest invasion).
  • Resectable disease defined by stage cT1-3, N0-1, M0 (I to IIIA) according to UICC
    TNM classification (8th edition). FDG-PET-CT scan with fusion images showing absence
    of M1, N2 involvement is required. Focal chest wall lesions are acceptable.
  • Tumor tissue available after completing chemotherapy and before starting treatment
    with DCT. Tumor tissue can be obtained by either a CT-guided needle biopsy or a
    VATS surgical biopsy.
  • Fit to receive platinum-based chemotherapy (as per standard of care of the treating
    physician/Institution) and undergo a P/D with optional removal of hemidiaphragm and
    pericardium. The responsible surgeon and chest physician should judge the required
    fitness prior to registration, taking into account the results of all the relevant (i.e. pulmonary,
    cardiac) examinations.

 Exclusiecriteria

Clinical or radiological invasion of mediastinal structures (heart, aorta, spine, esophagus,
etc.) and widespread chest wall invasion (stage T4). Involvement of N2 nodes.
Stage IV (metastatic disease).

Meer studies

Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie:

EVOKE

Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy